top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma Funding Update July 1st-5th ‘24

This week's biopharma funding and startup activity includes some significant milestones. Based in London, Myricx Bio closed £90M in Series A funding to advance its novel ADC payload platform. Kanvas Biosciences, from New Jersey, secured an additional $12.5M to progress its microbiome-based immuno-oncology pipeline.

Want to get this list of recently funded companies and more data? Fill out a quote request to get more info (Quote Request Form).

FIG. 1. Recent Biotech Funding Activity.

Private Funding –

Myricx Bio

💸  Closed £90M Series A financing to develop their novel ADC payload platform. 

Circle Pharma

💸  Sold $54.1M equity.

Kanvas Biosciences

💸  Secured an additional $12.5M to advance microbiome-based Immuno-oncology pipeline.


💸  Completed $7.3M oversubscribed Series A+ financing led by KGI Venture Capital to further ABT-301 Ph2 trials.

Granza Bio

💸  Raised $7.14M seed round led by Felicis and Refactor, with participation from Y Combinator to advance oncology and autoimmune treatment.

Post-IPO/Public Funding –

Cartesian Therapeutics

🏦  Secured $130M in financing for its pipeline programs and general corporate purposes.

BioNano Genomics

🏦  Announced a $30M public offering with $10M upfront and an additional $20M upon exercise of clinical milestone-linked warrants


🏦  Completed £28.9M fundraising to advance multiple GalOmic™ pipeline assets.


🏦  Announced full exercise of $17.9M Series H warrants following positive outcomes result from C-GUARDIAN trial.

Checkpoint Therapeutics

🏦  Raised $12M in a direct offering for working capital and corporate purposes.


Article History:

RF, DV, DG (07/09/24)

This article is not investment or legal advice.


bottom of page